

2026 Regular Session

HOUSE RESOLUTION NO. 174

BY REPRESENTATIVES OWEN, AMEDEE, BERAULT, WILFORD CARTER,
CARVER, HORTON, SCHAMERHORN, AND TAYLOR

A RESOLUTION

To urge and request the surgeon general and the Louisiana Department of Health to conduct a professional assessment of fenbendazole or similar potential treatments for cancer or other medical conditions, to evaluate state-level options for supporting further review, and to develop guidance on engaging the United States Food and Drug Administration for compassionate use, expanded access programs, or prioritized clinical trials, while maintaining rigorous patient safety and evidence-based standards.

WHEREAS, there is growing public interest in fenbendazole, a veterinary anthelmintic drug, due to an increasing number of anecdotal reports and patient testimonials from across the United States, including Louisiana, describing significant recoveries or remissions from various types of cancer after self-administration, often in conjunction with other therapies; and

WHEREAS, preclinical studies have indicated that fenbendazole may possess anti-tumor properties, such as disrupting microtubules in cancer cells and inhibiting tumor growth in laboratory models; and

WHEREAS, despite these preliminary findings, fenbendazole is not currently approved by the United States Food and Drug Administration for human use, and clinical evidence in humans remains limited to case reports and observational data without large-scale randomized controlled trials; and

WHEREAS, organizations such as the American Cancer Society have cautioned against the off-label use of fenbendazole outside of controlled clinical settings due to potential risks, including liver inflammation, and unknown drug interactions; and

WHEREAS, the experiences of the COVID-19 pandemic have highlighted the value of considering innovative and nontraditional treatment options during times of urgent

medical need, prompting many, including members of the Louisiana House of Representatives, to approach emerging therapies with a more open perspective, while still prioritizing patient safety; and

WHEREAS, rising cancer rates in Louisiana, and reports of residents seeking unverified sources of fenbendazole, raise important public health considerations that warrant formal evaluation by the state's chief health officer; and

WHEREAS, the expertise of the state surgeon general in public health policy and emerging therapies is essential to determining whether fenbendazole could offer a viable, expedited treatment option for patients facing limited alternatives.

THEREFORE, BE IT RESOLVED that the House of Representatives of the Legislature of Louisiana does hereby urge and request the surgeon general of this state to do all of the following:

(1) Provide a professional assessment and guidance regarding the feasibility of advancing fenbendazole or similar treatments toward potential human authorization for the treatment of cancer or other medical conditions, including any appropriate state-level steps this state could take to support, or advocate for, further scientific review.

(2) Develop a recommended plan for engaging federal authorities, including the United States Food and Drug Administration, to expedite evaluation of fenbendazole or similar treatments through compassionate use protocols, expanded access programs, or prioritization in clinical trials, while ensuring patient safety and adherence to evidence-based standards.

(3) Submit a written report of findings and recommendations to the House Committee on Health and Welfare no later than February 1, 2027.

BE IT FURTHER RESOLVED that a copy of this Resolution be transmitted to the surgeon general of this state and the secretary of the Louisiana Department of Health.

SPEAKER OF THE HOUSE OF REPRESENTATIVES